Ambrose Healthcare is proud to announce that our Chief Financial Officer, Ali Elsley, has been appointed Chair of the Board at Cambridge Rugby Club, Cambridge, UK.
This appointment marks a significant milestone, not only for the club, but for the wider sporting community. Ali becomes the first woman to serve as Chair of a rugby club competing in the national Champ Rugby league, the second highest level of professional rugby union in the UK.
Cambridge Rugby Club currently competes in Champ Rugby, the division below the Gallegher Prem, and plays a critical role in the development and progression of elite rugby talent in England.
Ali’s appointment reflects her exceptional leadership, strategic acumen, and track record of delivering growth and transformation across complex organisations. At Ambrose Healthcare, she has been instrumental in shaping our financial strategy, supporting our fundraising activities, and positioning the company for its next phase of growth as we advance our rare disease drug pipeline.

Ambrose Healthcare is delighted to announce the appointment of five exceptional senior leaders to its executive and operational team, marking a significant step forward in the company’s growth and strategic trajectory.
These appointments bring together deep expertise across finance, strategy, regulatory affairs, manufacturing, and intellectual property, further strengthening Ambrose’s capability to advance its rare disease pipeline and deliver long-term value to patients and investors.

Rare Disease Day marks a global moment of reflection and resolve.

More than 300 million people worldwide live with a rare condition. Many are children. Many face delayed diagnosis. For most rare diseases, approved therapeutic options remain limited or non-existent.
While scientific innovation continues to accelerate, translation into accessible treatment remains uneven. Rare disease is not a marginal issue, it is a structural healthcare challenge requiring coordinated action across science, clinical delivery, regulation and capital.

At Ambrose Healthcare, we believe the next phase of rare disease progress must move beyond awareness toward disciplined execution.

Ambrose Healthcare is delighted to announce the appointment of Virág Stephens as Chief of Staff, supporting CEO Toby Waterworth and COO Dr Hazel Jones in delivering our ambitious growth and fundraising strategy. 

Ambrose Healthcare, an emerging bio-pharmaceutical company focused on transforming the management of rare diseases through therapeutics and AI-powered diagnostics, is pleased to announce the appointment of Dr. Hazel Jones as Chief Operating Officer (COO). In her new role, Hazel will lead operational strategy and execution across Ambrose, bringing her extensive leadership experience in healthcare innovation to the forefront of Ambrose’s rare disease mission.

Ambrose Healthcare Ltd is pleased to announce that it has exercised the previously granted option to license the novel oncology therapeutic VAL401 from ValiSeek Limited, a joint-venture subsidiary of ValiRx plc, under the terms of the Option Agreement announced on 5 December 2023

Ambrose Healthcare Ltd. is delighted to announce that it has won the Best Startup Biotech Company Award at the prestigious OBN Awards 2024, held on 20 November in London.

Ambrose Healthcare Ltd reports that the option to acquire renzapride has been exercised, providing global ownership rights.

Ambrose Healthcare publishes new white paper summarizing regulatory mechanisms to stimulate development of new rare disease treatments.

Ambrose Healthcare has been named a finalist in the prestigious OBN Awards 2024, under the category of Best Start-Up Biotech Company.

Ambrose Healthcare Ltd has appointed an accomplished Medical Advisory Board to support the development of its growing pipeline.

Our founder Toby considers recent acquisitions and their significance.

Our CEO Toby explores what may lay ahead for 2024 in rare disease after a tough year for many.

Our founder Toby explains why Ambrose was heading to Arab Health at a time when many would prioritize JP Morgan's congress.

We're delighted to be featured in MediWales LifeStories Magazine!

Ambrose Healthcare crowned National Life Sciences Start-Up of the Year at the annual MediWales Innovation Awards.

ValiRX CEO discusses the agreement in a 5-min video interview

ValiRx Plc (AIM: VAL), announces that ValiSeek Limited (“ValiSeek”) has entered into an exclusive Option Agreement to license VAL401 with Ambrose Healthcare Limited.

Ambrose Healthcare is accelerating innovation in rare disease drug development and today we've summarized three important themes in a new white paper.

Ambrose announces announce the broadening of its network of collaborators with the joining of Aparito.